Parallel	O
artificial	B:C0025256
liquid	I:C0025256
membrane	I:C0025256
extraction	O
of	O
new	O
psychoactive	O
substances	I:C0682880
in	O
plasma	O
and	O
whole	O
blood	I:C0370231
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	B:C0684295
of	O
new	O
psychoactive	O
substances	I:C0682880
in	O
plasma	O
and	O
whole	O
blood	I:C0370231
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
of	O
new	O
psychoactive	B:C0682880
substances	I:C0682880
in	O
plasma	O
and	O
whole	O
blood	I:C0370231
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
of	O
new	O
psychoactive	O
substances	I:C0682880
in	O
plasma	B:C0032105
and	O
whole	O
blood	I:C0370231
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
of	O
new	O
psychoactive	O
substances	I:C0682880
in	O
plasma	O
and	O
whole	B:C0370231
blood	I:C0370231
.	O

Parallel	O
artificial	B:C0025256
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	B:C0684295
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	B:C0684295
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	B:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	B:C4053724
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	B:C0220908
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	B:C0682880
substances	I:C0682880
(	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	O
artificial	O
liquid	I:C0025256
membrane	I:C0025256
extraction	O
(	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
)	O
was	O
combined	O
with	O
ultra-high	O
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
(	O
ultra	O
-	I:C4053724
high	I:C4053724
performance	I:C4053724
liquid	I:C4053724
chromatography	I:C4053724
-	I:C4053724
mass	I:C4053724
spectrometry	I:C4053724
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	I:C0682880
(	O
new	B:C0682880
psychoactive	I:C0682880
substances	I:C0682880
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

Parallel	B:C0684295
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
in	O
96	O
-	O
well	O
format	O
comprising	O
a	O
donor	O
plate	O
,	O
a	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
(	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
in	O
96	O
-	O
well	B:C4283957
format	O
comprising	O
a	O
donor	O
plate	O
,	O
a	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
(	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
in	O
96	O
-	O
well	O
format	O
comprising	O
a	O
donor	B:C3263710
plate	O
,	O
a	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
(	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
in	O
96	O
-	O
well	O
format	O
comprising	O
a	O
donor	O
plate	O
,	O
a	O
supported	B:C0025256
liquid	I:C0025256
membrane	I:C0025256
(	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
in	O
96	O
-	O
well	O
format	O
comprising	O
a	O
donor	O
plate	O
,	O
a	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
(	O
supported	B:C0025256
liquid	I:C0025256
membrane	I:C0025256
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Uncharged	O
new	B:C0682880
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
plasma	O
or	O
whole	O
blood	I:C0370231
,	O
across	O
an	O
organic	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

Uncharged	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	B:C0684295
from	O
plasma	O
or	O
whole	O
blood	I:C0370231
,	O
across	O
an	O
organic	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

Uncharged	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
plasma	B:C0032105
or	O
whole	O
blood	I:C0370231
,	O
across	O
an	O
organic	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

Uncharged	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
plasma	O
or	O
whole	B:C0370231
blood	I:C0370231
,	O
across	O
an	O
organic	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

Uncharged	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
plasma	O
or	O
whole	O
blood	I:C0370231
,	O
across	O
an	O
organic	O
supported	B:C0025256
liquid	I:C0025256
membrane	I:C0025256
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

5,6-methylenedioxy-2-aminoindane	B:C0081183
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	B:C0081183
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	B:C0910385
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	B:C0048271
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	B:C0048271
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	B:C0044170
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	B:C0044170
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	B:C3492415
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	B:C3253535
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	B:C0622071
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	B:C1254351
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	B:C1254351
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	B:C2715878
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	B:C0051008
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	B:C0051008
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
.	O

5,6-methylenedioxy-2-aminoindane	O
(	O
5,6-methylenedioxy	O
-2-aminoindane	I:C0081183
)	O
,	O
methylone	O
,	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
(	O
para	O
-	I:C0048271
fluoroamphetamine	I:C0048271
)	O
,	O
meta-chlorophenylpiperazine	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C	O
-	I:C1254351
E	I:C1254351
(	O
2,5	O
-	I:C1254351
dimethoxy-4-ethylphenethylamine	I:C1254351
)	O
,	O
bromo-	O
dragonfly	I:C2715878
,	O
and	O
AH	O
-	I:C0051008
7921	I:C0051008
(	O
3,4	O
-	I:C0051008
dichloro-N-{[1-(	I:C0051008
dimethylamino	I:C0051008
)	I:C0051008
cyclohexyl]methyl}benzamide	I:C0051008
)	O
were	O
selected	O
as	O
representative	O
new	B:C0682880
psychoactive	I:C0682880
substances	I:C0682880
.	O

Optimization	O
of	O
operational	O
parameters	O
was	O
necessary	O
as	O
the	O
new	B:C0682880
psychoactive	I:C0682880
substances	I:C0682880
were	O
novel	O
to	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
,	O
and	O
because	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
from	O
whole	O
blood	I:C0370231
for	O
the	O
very	O
first	O
time	O
.	O

Optimization	O
of	O
operational	O
parameters	O
was	O
necessary	O
as	O
the	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
novel	O
to	O
Parallel	B:C0684295
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
,	O
and	O
because	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
from	O
whole	O
blood	I:C0370231
for	O
the	O
very	O
first	O
time	O
.	O

Optimization	O
of	O
operational	O
parameters	O
was	O
necessary	O
as	O
the	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
novel	O
to	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
,	O
and	O
because	O
Parallel	B:C0684295
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
from	O
whole	O
blood	I:C0370231
for	O
the	O
very	O
first	O
time	O
.	O

Optimization	O
of	O
operational	O
parameters	O
was	O
necessary	O
as	O
the	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
novel	O
to	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
,	O
and	O
because	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
was	O
performed	O
from	O
whole	B:C0370231
blood	I:C0370231
for	O
the	O
very	O
first	O
time	O
.	O

In	O
the	O
Parallel	B:C0684295
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	B:C0025663
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	B:C0032105
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	B:C0682880
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	B:C0684295
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	B:C1551382
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	B:C3263710
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	B:C0032105
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
developed	O
for	O
plasma	O
,	O
new	O
psychoactive	I:C0682880
substances	I:C0682880
were	O
extracted	O
from	O
a	O
250μL	O
alkalized	O
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40	O
mM	O
NaOH	B:C0037517
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	B:C0684295
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
from	O
whole	O
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	O
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	B:C0025663
from	O
whole	O
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	O
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
from	O
whole	B:C0370231
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	O
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
from	O
whole	O
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	B:C1551382
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
from	O
whole	O
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	O
donor	B:C3263710
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
from	O
whole	O
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	O
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	B:C0370231
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
the	O
Parallel	O
artificial	I:C0684295
liquid	I:C0684295
membrane	I:C0684295
extraction	I:C0684295
method	O
from	O
whole	O
blood	I:C0370231
,	O
the	O
250μL	O
alkalized	O
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	I:C0370231
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80	O
mM	O
NaOH	B:C0037517
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
both	O
method	B:C0025663
s	O
,	O
extraction	O
was	O
accomplished	O
across	O
an	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	O
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	O
acid	I:C0016576
.	O

In	O
both	O
method	O
s	O
,	O
extraction	B:C0684295
was	O
accomplished	O
across	O
an	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	O
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	O
acid	I:C0016576
.	O

In	O
both	O
method	O
s	O
,	O
extraction	O
was	O
accomplished	O
across	O
an	O
supported	B:C0025256
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	O
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	O
acid	I:C0016576
.	O

In	O
both	O
method	O
s	O
,	O
extraction	O
was	O
accomplished	O
across	O
an	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	B:C0623374
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	O
acid	I:C0016576
.	O

In	O
both	O
method	O
s	O
,	O
extraction	O
was	O
accomplished	O
across	O
an	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	O
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	B:C0076985
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	O
acid	I:C0016576
.	O

In	O
both	O
method	O
s	O
,	O
extraction	O
was	O
accomplished	O
across	O
an	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	O
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	B:C0001128
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	O
acid	I:C0016576
.	O

In	O
both	O
method	O
s	O
,	O
extraction	O
was	O
accomplished	O
across	O
an	O
supported	O
liquid	I:C0025256
membrane	I:C0025256
of	O
5μL	O
dodecyl	O
acetate	I:C0623374
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20	O
mM	O
formic	B:C0016576
acid	I:C0016576
.	O

The	O
extraction	B:C0684295
was	O
promoted	O
by	O
agitation	O
at	O
900	O
rpm	O
and	O
was	O
carried	O
out	O
for	O
120	O
min	O
.	O

Method	B:C0025663
validation	O
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	O
recoveries	O
,	O
carry	O
-	O
over	O
,	O
and	O
matrix	O
effects	O
.	O

Method	O
validation	B:C1519941
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	O
recoveries	O
,	O
carry	O
-	O
over	O
,	O
and	O
matrix	O
effects	O
.	O

Method	O
validation	O
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	B:C0684295
recoveries	O
,	O
carry	O
-	O
over	O
,	O
and	O
matrix	O
effects	O
.	O

Method	O
validation	O
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	O
recoveries	O
,	O
carry	O
-	O
over	B:C0205136
,	O
and	O
matrix	O
effects	O
.	O

Method	O
validation	O
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	O
recoveries	O
,	O
carry	O
-	O
over	O
,	O
and	O
matrix	B:C4050026
effects	O
.	O

The	O
validation	O
results	O
were	O
in	O
accordance	O
with	O
FDA	B:C0041714
guidelines	O
.	O

The	O
validation	O
results	O
were	O
in	O
accordance	O
with	O
FDA	O
guidelines	B:C0162791
.	O

